drugset / Trial / NCT03028766
WEE1 Inhibitor with Cisplatin and Radiotherapy: a Trial in Head and Neck Cancer
Phase 1
Completed
9 enrolled
University of Birmingham
AstraZeneca · collabCancer Research UK · collab
Non-randomizedParallel-groupOpen-labelTreatment
Summary
This trial is to determine what dose of a drug called AZD1775 can safely be given in combination with cisplatin before surgery and with chemo-radiotherapy after surgery in patients with Head and Neck Cancer. The Investigators will also get some preliminary information regarding the effectiveness of this combined treatment.
Timeline
- Start
- 2017-06-22
- Primary completion
- 2019-10-31
- Completion
- 2021-02-03
Publications
- Background Kong A, Kirkham AJ, Savage JS, Mant R, Lax S, Good J, Forster MD, Sacco JJ, Schipani S, Harrington KJ, Yap C, Mehanna H. Results and lessons learnt from the WISTERIA phase I trial combining AZD1775 with cisplatin pre- or post-operatively in head and neck cancer. BJC Rep. 2024;2(1):6. doi: 10.1038/s44276-023-00026-6. Epub 2024 Jan 29.
- Background Kong A, Good J, Kirkham A, Savage J, Mant R, Llewellyn L, Parish J, Spruce R, Forster M, Schipani S, Harrington K, Sacco J, Murray P, Middleton G, Yap C, Mehanna H. Phase I trial of WEE1 inhibition with chemotherapy and radiotherapy as adjuvant treatment, and a window of opportunity trial with cisplatin in patients with head and neck cancer: the WISTERIA trial protocol. BMJ Open. 2020 Mar 16;10(3):e033009. doi: 10.1136/bmjopen-2019-033009.
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Adavosertib | Small molecule | — | Oral |
| Subject | Cisplatin | Other / unclassified | 40 mg/m2 | Intravenous |